Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Lovelace Biomedical Research Institute
EIR
•Lovelace Biomedical Research Institute•January 31, 2020

Lovelace Biomedical Research Institute – FDA EIR, Jan 31, 2020

Record Details

An FDA inspection was conducted at Lovelace Biomedical Research Institute in Albuquerque, NM, from January 27 to January 31, 2020. This routine inspection, focusing on Good Laboratory Practice (GLP) for nonclinical studies supporting FDA marketing applications, uncovered several critical compliance deficiencies. At the conclusion of the inspection, the firm was issued an FDA Form 483 citing two main violations: a failure to retain all raw data generated from a nonclinical laboratory study and a failure to ensure that challenge agents were appropriately tested for identity. Further findings detailed throughout the inspection reports included a consistent lack of robust data integrity practices. Specifically, inspectors noted instances of missing non-GLP study records, inadequate characterization of test materials, unverified or retrospectively altered data entries, and insufficient justification for data changes. Significant issues were also identified in protocol deviation documentation, reconciliation of manual and electronic records, and the management of archival processes for non-GLP materials. Additionally, practices such as pre-signed study director forms and inconsistent application of critical observation criteria raised concerns about study oversight. Lovelace Biomedical Research Institute acknowledged the observations outlined in the FDA Form 483, and while immediate corrective actions were not promised during the close-out, a written response was subsequently received. These findings underscore the necessity for the institute to implement comprehensive improvements in its data management, record retention, and overall adherence to GLP regulations governing nonclinical research.

Company
Lovelace Biomedical Research Institute
Inspection date
January 31, 2020
Product type
Biologics
Office
Denver District Office
People
  • Mark J. Seaton (issuing_officer)
  • Erin M. McDowell (other)
  • Theressa B. Smith
  • Jonathan R. Campos
View Company Profile

ID · 3283069b-e147-4687-b90a-8e7817e7ea84

Other documents for Lovelace Biomedical Research Institute
  • WARNING_LETTER - 2025-04-18April 18, 2025
  • 483 - 2025-04-18April 18, 2025
  • 483 - 2020-01-27January 27, 2020
  • EIR - 2019-09-13September 13, 2019
  • 483 - 2019-09-13September 13, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Lovelace Biomedical Research Institute
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.